|
1
|
Fennell DA, Summers Y, Cadranel J, Benepal
T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C and Ferry
D: Cisplatin in the modern era: The backbone of first-line
chemotherapy for non-small cell lung cancer. Cancer Treat Rev.
44:42–50. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shi Y and Sun Y: Medical management of
lung cancer: Experience in China. Thorac Cancer. 6:10–16. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hong JH, Hwang ES, McManus MT, Amsterdam
A, Tian Y, Kalmukova R, Mueller E, Benjamin T, Spiegelman BM, Sharp
PA, et al: TAZ, a transcriptional modulator of mesenchymal stem
cell differentiation. Science. 309:1074–1078. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhao B, Tumaneng K and Guan KL: The Hippo
pathway in organ size control, tissue regeneration and stem cell
self-renewal. Nat Cell Biol. 13:877–883. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dupont S, Morsut L, Aragona M, Enzo E,
Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M,
Bicciato S, et al: Role of YAP/TAZ in mechanotransduction. Nature.
474:179–183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang K, Qi HX, Hu ZM, Chang YN, Shi ZM,
Han XH, Han YW, Zhang RX, Zhang Z, Chen T, et al: YAP and TAZ take
center stage in cancer. Biochemistry. 54:6555–6566. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou Z, Hao Y, Liu N, Raptis L, Tsao MS
and Yang X: TAZ is a novel oncogene in non-small cell lung cancer.
Oncogene. 30:2181–2186. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xie M, Zhang L, He CS, Hou JH, Lin SX, Hu
ZH, Xu F and Zhao HY: Prognostic significance of TAZ expression in
resected non-small cell lung cancer. J Thorac Oncol. 7:799–807.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim MH and Kim J: Role of YAP/TAZ
transcriptional regulators in resistance to anti-cancer therapies.
Cell Mol Life Sci. 74:1457–1474. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lai D, Ho KC, Hao Y and Yang X: Taxol
resistance in breast cancer cells is mediated by the hippo pathway
component TAZ and its downstream transcriptional targets
Cyr61 and CTGF. Cancer Res. 71:2728–2738. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yoshikawa K, Noguchi K, Nakano Y, Yamamura
M, Takaoka K, Hashimoto-Tamaoki T and Kishimoto H: The Hippo
pathway transcriptional co-activator, YAP, confers resistance to
cisplatin in human oral squamous cell carcinoma. Int J Oncol.
46:2364–2370. 2015.PubMed/NCBI
|
|
12
|
Ciamporcero E, Shen H, Ramakrishnan S, Ku
S Yu, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti
S, et al: YAP activation protects urothelial cell carcinoma from
treatment-induced DNA damage. Oncogene. 35:1541–1553. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xiao L, Shi XY, Zhang Y, Zhu Y, Zhu L,
Tian W, Zhu BK and Wei ZL: YAP induces cisplatin resistance through
activation of autophagy in human ovarian carcinoma cells. Onco
Targets Ther. 9:1105–1114. 2016.PubMed/NCBI
|
|
14
|
Xu W, Wei Y, Wu S, Wang Y, Wang Z, Sun Y,
Cheng SY and Wu J: Up-regulation of the Hippo pathway effector TAZ
renders lung adenocarcinoma cells harboring EGFR-T790M mutation
resistant to gefitinib. Cell Biosci. 5:72015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Amable L: Cisplatin resistance and
opportunities for precision medicine. Pharmacol Res. 106:27–36.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu JL, Wang ZW, Hu LM, Yin ZQ, Huang MD,
Hu ZB, Shen HB and Shu YQ: Genetic variants in the
PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy
response of advanced non-small cell lung cancers in a Chinese
population. Asian Pac J Cancer Prev. 13:2157–2162. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Noguchi S, Saito A, Horie M, Mikami Y,
Suzuki HI, Morishita Y, Ohshima M, Abiko Y, Mattsson JS, König H,
et al: An integrative analysis of the tumorigenic role of TAZ in
human non-small cell lung cancer. Clin Cancer Res. 20:4660–4672.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Moroishi T, Hansen CG and Guan KL: The
emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 15:73–79.
2015. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo L and Teng L: YAP/TAZ for cancer
therapy: Opportunities and challenges (Review). Int J Oncol.
46:1444–1452. 2015.PubMed/NCBI
|
|
20
|
Bartucci M, Dattilo R, Moriconi C,
Pagliuca A, Mottolese M, Federici G, Benedetto AD, Todaro M, Stassi
G, Sperati F, et al: TAZ is required for metastatic activity and
chemoresistance of breast cancer stem cells. Oncogene. 34:681–690.
2015. View Article : Google Scholar : PubMed/NCBI
|
